<DOC>
	<DOCNO>NCT00727987</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness golimumab patient active rheumatoid arthritis despite Methotrexate therapy . Another objective evaluate pharmacokinetics golimumab .</brief_summary>
	<brief_title>A Safety Efficacy Study Golimumab ( CNTO 148 ) Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
	<detailed_description>This clinical study schedule perform purpose evaluate safety effectiveness golimumab ( CNTO148 ) administer combination stable dose ( 6-8mg/week ) methotrexate ( MTX ) patient rheumatoid arthritis ( RA ) . CNTO148 50 mg group : CNTO148 50 mg SC injection every 4 week first administration week 152 . If early escape , 100 mg SC injection every 4 week week 16 week 152 . CNTO148 100 mg group : CNTO148 100 mg SC injection every 4 week first administration week 152 whether early escape Placebo group : Placebo SC injection every 4 week first administration week 20 CNTO148 50mg SC injection every 4 week week 16 week 152</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients diagnose rheumatoid arthritis least 3 month prior registration definitely identify rheumatoid arthritis , time informed consent , accord criterion classification establish American College Rheumatology ( 1987 ) Patients MTX therapy ( &gt; = 6 mg/week ) start 3 month first administration treat MTX stable dose ( 68 mg/week ) least 4 week first administration Patients least 4 swollen joint least 4 tender joint time registration immediately first administration . Patients history hypersensitivity human immunoglobulin proteins ingredient golimumab Patients previously experience suffer follow disease : ( ) Collagen disease rheumatoid arthritis , ( ii ) Latent active granulomatous infection histoplasmosis coccidioidomycosis , ( iii ) Felty syndrome , etc Patients severe , advanced , poorly control disease kidney , liver , blood , gastrointestinal system , endocrine system , lung , heart , nervous system , psychiatric system , brain .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Fully Human anti-TNFa monoclonal antibody</keyword>
	<keyword>CNTO148</keyword>
	<keyword>Golimumab</keyword>
</DOC>